Calix released second quarter 2026 financial results on July 20, 2026, with the earnings conference call scheduled for July 21. Revenue and adjusted earnings per share exceeded analyst consensus estimates.

Net revenue reached a record $142.6 million, up 4.2% year-over-year. Diluted EPS rose 23.6% to $1.78, exceeding prior-year levels.

Net income rose to $16.3 million, or $0.96 per diluted share, up from $11.7 million, or $0.69 per share, in Q2 2025. Operating earnings per diluted share reached $0.96, beating analyst estimates of $0.92.

Net income reached $16.0 million, or $0.83 per diluted share, for the quarter ended June 30, 2026, up from $12.6 million, or $0.66 per diluted share, in Q1 2026. Results exceeded analyst expectations, with net interest income reported at $41.803 million.

Home Bancorp, Inc. reported net income of $11.6 million for the 2026 second quarter ended June 30, 2026. Diluted earnings per share (EPS) reached $1.48, exceeding the consensus estimate of $1.46 by $0.02.

RBB Bancorp reported net income of $10.1 million for the second quarter ended June 30, 2026. Diluted earnings per share reached $0.59, exceeding the consensus estimate of $0.52.

IREN surged +18.2% during Monday's regular trading session, rebounding from Friday's close of $33.62 to approximately $39.74, snapping a seven-session losing streak. The rally was driven by the company announcing $2.8 billion in new multiyear AI cloud contracts with leading developers, including Microsoft, Nvidia, and Perplexity.

SFBS and SFNC are both regional bank holding companies operating primarily in the southeastern United States, with comparable business models focused on commercial and consumer banking services. Both companies released or are scheduled to release second-quarter 2026 earnings in mid-July, providing fresh data on net interest income (NII), loan growth, and deposit trends amid a stable interest-rate environment.

STAA shares fell -11.42% during Monday's regular session to $23.42, extending Friday's -8.76% rout for a combined two-day decline of roughly -19%. The sell-off originated from Thursday's preliminary Q2 revenue announcement, which beat estimates at $90M+ but lacked any second-half 2026 guidance, sparking analyst caution.

IMMX dropped -13.27% during Monday's regular session after STAT News revealed its CMO "Richard Graydon" was actually Ronald Fischer, a fugitive convicted of sexual assault who spent 20 years evading authorities. The company disclosed Graydon's termination in a July 17 SEC filing but omitted the fugitive connection, stating his departure was "for reasons unrelated to his activities at the Company."

STDN fell approximately -10.30% during Monday's regular session, extending a brutal post-IPO selloff into its third consecutive trading day since debuting July 16. The stock opened at $10.80 but quickly reversed lower after a brief premarket bounce of +3.75% evaporated early in the session.

PVLA plunged -19.21% during Monday's regular trading session, tumbling from Friday's close of $157.24 to approximately $127.04, erasing much of last week's gains. The selloff represents a classic "sell-the-news" profit-taking event after shares recently surged to a 52-week high of $161.38, fueled by FDA granting a rolling review for the company's QTORIN rapamycin NDA submission.

Price Target: $50 per share — a psychological round number just below FBL's 52-week high of $51.72 and roughly 67% above its mid-July 2026 trading level near $30. Strongest Bullish Factor: As a 2x leveraged ETF tied to META (Meta Platforms), any sustained rally in Meta's stock would be magnified, potentially propelling FBL toward the target rapidly.

FBL surged approximately 26% in the trailing 30-day period, reflecting a sharp recovery in its sole underlying holding, META (Meta Platforms, Inc.), which posted a 21% intra-month gain in July alone. Over the same quarter, FBL declined roughly 15%, highlighting the extreme two-way volatility characteristic of a 2x leveraged single-stock ETF.

PENG shares fell -9.58% during regular trading on Monday, dropping to $54.62 from Friday's close of $60.41, extending a brutal multi-session selloff from last week's highs above $83. The primary catalyst was a Barclays downgrade to Underweight from Equal Weight with a $40 price target, citing that the stock's sharp rally has outpaced fundamentals and that recent earnings strength was driven by higher memory prices rather than sustainable advanced-computing growth.

MAAS is trading at $17.50 during Monday's regular session, down -11.44% from Friday's close of $19.76, extending a two-session selloff that began after the company's July 17 strategic announcement. The primary catalyst is investor unease over the company's decision to sell its 49% indirect stake in Qingdao Huiju Laixi Intelligent (an unmanned car wash business) to Galaxicore for $17 million, exiting a tangible operating asset to double down on unproven AI infrastructure.

BE shares are trading down -7.23% during Monday's regular session, extending a brutal selloff that has now erased roughly 43% from its late-June all-time high of $351.28. The primary overhang remains the Hunterbrook short report from early July alleging Bloom secretly relies on Chinese scandium oxide supply, undermining the company's production scalability claims and shaking investor confidence in the AI-power growth narrative.

TEM shares tumbled -8.94% during Monday's regular session, falling from Friday's close of $52.47 to approximately $47.78, after opening sharply lower following premarket weakness. The primary catalyst is Tempus AI's announcement that it will acquire cancer-test maker Personalis (PSNL) in an all-stock deal valued at $1.5 billion, at $16.25 per share — a transaction viewed by investors as dilutive and costly for a company still reporting net losses.

Crown Holdings (CCK) gained approximately 15.4% over the last 30 days, climbing from $101.54 on June 18 to $117.21 by July 17, 2026. A breakout above the prior 52-week high of $116.62 and a Raymond James price-target increase to $135 fueled bullish momentum.

XOM shares closed at $147.36 on July 17, 2026, reflecting a 6.9% gain over the trailing 30-day period as the stock recovered from a mid-June selloff that briefly took prices below $135. ExxonMobil signaled that Q2 2026 upstream earnings will benefit by $3.5–$3.9 billion from elevated crude prices, with additional margin gains of $3.0–$3.6 billion across its Energy Products and Chemical Products segments.